Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Guidance programme
Guidance programme
Technology appraisal guidance (11)
Apply filters
Showing 1 to 11 of 11
Sort by
Title
Date
Apply sorting
Keyword or reference number: Atezolizumab
`Remove $Keyword or reference number: Atezolizumab filter`
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Atezolizumab
(Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]
Technology appraisal guidance
TBC
Atezolizumab
as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]
Technology appraisal guidance
TBC
Atezolizumab
for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]
Technology appraisal guidance
TBC
Atezolizumab
for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Technology appraisal guidance
TBC
Atezolizumab
with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]
Technology appraisal guidance
TBC
Atezolizumab
with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]
Technology appraisal guidance
TBC
Lurbinectedin with
atezolizumab
for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]
Technology appraisal guidance
2 December 2026
Tiragolumab with
atezolizumab
and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]
Technology appraisal guidance
TBC
Tiragolumab with
atezolizumab
for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]
Technology appraisal guidance
TBC
Tiragolumab with
atezolizumab
for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]
Technology appraisal guidance
TBC
Tiragolumab with
atezolizumab
for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]
Technology appraisal guidance
TBC
Current page
1
Page
1
of
1
Results per page
10
25
50
All
Back to top